The recall that put specialised nutrition under pressure
Danone was one of several manufacturers caught in a cereulide contamination event in late 2025 that triggered a product recall spanning nearly 100 countries, covering formula, nutritional products, and oil mixes, according to reporting from Dairy Reporter. Nestlé and Lactalis were also named in the same recall. That breadth is significant: a recall touching 100 markets simultaneously is not a localised factory problem but a signal of how deeply integrated and exposed global infant-formula supply chains have become.
Cereulide is a heat-stable toxin produced by Bacillus cereus. Unlike many bacterial contaminants, it survives standard processing temperatures, which makes detection and removal genuinely difficult. The same Dairy Reporter analysis noted that around the same time, the US recorded what investigators described as the first botulism outbreak epidemiologically linked to powdered infant formula. Two major safety events in one reporting period, in the same category, is not coincidence. It is a structural gap in manufacturing and testing practices that regulators and buyers are now paying close attention to.
Why this moment is particularly sensitive for Danone
Danone's specialised nutrition division, which includes infant formula and medical nutrition, is one of the company's three core reporting segments. The business has faced years of pressure, particularly in China, where birth rates have declined and domestic formula brands have taken share. A large-scale safety recall in this environment compounds an already difficult operating picture.
Danone's FY 2025 press release reported €27,283 million in total sales, up 4.5% on a like-for-like basis. Volume and mix contributed 2.7 percentage points, while pricing contributed 1.8 percentage points. That is a meaningful structural shift: for three years, Danone and most of its peers grew primarily by raising prices. Now, growth depends on selling more units. When volume is the engine, manufacturing reliability and ingredient sourcing become the variables that can make or break a quarter.
The Synlait signal
Synlait Milk, a New Zealand dairy and infant-formula company, announced on 14 May that CEO Richard Wyeth had stepped down after roughly one year in the role, per a Just Food report. Director Leon Fung was named acting CEO immediately. Wyeth had joined Synlait in May 2024 after four years at Westland Milk Products. The board acknowledged a "particularly challenging period" for the business.
Synlait is not a Danone-owned entity, but its repeated leadership turnover and heavy losses are a proxy for conditions across the New Zealand dairy processing sector that supplies ingredients and finished product into global infant nutrition chains. When a key regional supplier is on its second acting CEO in just over a year, procurement teams at buyers like Danone face harder conversations about continuity, quality assurance, and contingency sourcing. Supplier instability is a supply-chain risk even when the supplier relationship is arm's length.
What the numbers say about cost and resilience trade-offs
The shift from price-led to volume-led growth changes the supply-chain calculus in a direct way. Price increases, while painful for shoppers, tend to improve unit margins without requiring additional throughput. Volume growth requires the factories to actually run more product. If capacity is tight, or if a recall has pulled product off the line, the cost of recovery is higher.
Danone's full-year 2025 results, per the company press release, showed Q4 like-for-like growth of 4.7%, confirming the volume momentum held into the final quarter. That sustained performance suggests manufacturing throughput is broadly functional. But a near-100-country recall, even one that has since been managed, leaves a mark on retailer confidence and regulatory scrutiny that does not disappear with the next earnings release.
What to watch next
Three things are worth tracking. First, how Danone discloses any financial impact from the cereulide recall in its next results communication, whether through direct charges, one-off costs, or a softer specialised nutrition performance line. Second, whether the company moves to accelerate dual-sourcing or in-house manufacturing for critical formula ingredients, a resilience investment that would add cost but reduce single-point-of-failure exposure. Third, how regulators in key markets, particularly the EU, the US, and China, respond to the twin 2025 safety events with new testing requirements or traceability mandates that would raise the compliance bar across the whole sector.
For commercial leaders working with or alongside Danone, the near-term read is straightforward: the company's supply chain is under more external pressure than its headline sales growth suggests. Volume momentum is real, but it sits on top of a specialised nutrition business navigating both safety scrutiny and upstream supplier fragility at the same time.